Novavax cuts headcount by 25%, hitting hundreds of jobs, to align costs with dwindling COVID-19 market

Novavax is reducing its head count by 25%. After trying to cut costs without laying off staff, the vaccine company has now accepted it will need to part ways with hundreds of employees to align its spending with the dwindling size of the COVID-19 opportunity.